Want to see AUTL full AI Analyst Report?
AUTL Stock Chart & Stats
$2.36
-$0.07(-4.61%)
At close: 4:00 PM EDT
$2.36
-$0.07(-4.61%)
Day’s Range― - ―
52-Week Range$1.18 - $2.58
Previous CloseN/A
Volume717.00K
Average Volume (3M)1.66M
Market Cap
$441.82M
Enterprise Value$590.54M
Total Cash (Recent Filing)$201.63M
Total Debt (Recent Filing)$83.51M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Oct 29, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding266,162,540
10 Day Avg. Volume1,869,220
30 Day Avg. Volume1,659,032
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.97
Price to Sales (P/S)7.01
P/FCF Ratio-1.70
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue5.03
Enterprise Value/Gross Profit32.13
Enterprise Value/Ebitda-2.67
Forecast
1Y Price Target
$7.70Price Target Upside226.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$149.40M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue GrowthRapidly increasing AUCATZYL revenue indicates meaningful commercial adoption and expanding demand rather than a purely development-stage business. Higher sales provide a growing base to absorb fixed costs, support investment in the pipeline, and improve the potential for operating leverage over the next several quarters.
Gross Margin ImprovementThe sharp margin improvement demonstrates that higher volumes and operational efficiencies are translating into better unit economics. If the stated mature-margin target is achieved, incremental product revenue could contribute more effectively to funding commercialization and clinical development while reducing reliance on external capital.
Expanding Commercial FootprintA broader treatment-center network increases patient access and creates a durable channel for AUCATZYL adoption. Expansion across the United States and the United Kingdom also supports future volume growth by embedding the therapy in more clinical settings and widening the company’s commercial reach.
Bears Say
Persistent Losses And Cash BurnAutolus remains dependent on substantial external funding because operating activities continue to consume significant cash and the company has not reached profitability. Persistent losses reduce financial flexibility and make successful revenue growth, margin expansion, and disciplined spending essential to sustaining operations.
Milestone-Contingent Secured FinancingThe financing improves near-term liquidity but does not provide unconditional access to the full facility. Future funding depends partly on commercial execution, while secured obligations and liquidity requirements can constrain flexibility and increase the consequences of missing revenue milestones.
High Commercialization And R&D CostsAutolus is spending heavily to commercialize AUCATZYL while continuing multiple clinical programs, so revenue growth has not yet produced sustainable profitability. Elevated SG&A and R&D can delay breakeven and maintain pressure on cash resources even as the commercial platform expands.
Autolus Therapeutics News
AUTL FAQ
What was Autolus Therapeutics Plc’s price range in the past 12 months?
Autolus Therapeutics Plc lowest stock price was $1.18 and its highest was $2.58 in the past 12 months.
What is Autolus Therapeutics Plc’s market cap?
Autolus Therapeutics Plc’s market cap is $441.82M.
When is Autolus Therapeutics Plc’s upcoming earnings report date?
Autolus Therapeutics Plc’s upcoming earnings report date is Oct 29, 2026 which is in 6 days.
How were Autolus Therapeutics Plc’s earnings last quarter?
Autolus Therapeutics Plc released its earnings results on Aug 11, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.194 by $0.044.
Is Autolus Therapeutics Plc overvalued?
According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued.
Does Autolus Therapeutics Plc pay dividends?
Autolus Therapeutics Plc does not currently pay dividends.
What is Autolus Therapeutics Plc’s EPS estimate?
Autolus Therapeutics Plc’s EPS estimate is -0.16.
How many shares outstanding does Autolus Therapeutics Plc have?
Autolus Therapeutics Plc has 266,162,540 shares outstanding.
What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?
Autolus Therapeutics Plc reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.194. Following the earnings report the stock price went up 12.56%.
Which hedge fund is a major shareholder of Autolus Therapeutics Plc?
Currently, no hedge funds are holding shares in AUTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Autolus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.70 (226.27% Upside)
$7.70 (226.27% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth $15.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.93%
12-Months-Change
Fundamentals
Return on Equity
-178.58%
Trailing 12-Months
Asset Growth
-31.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Autolus Therapeutics Plc
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
AUTL Company Deck
AUTL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum for AUCATZYL with substantial QoQ and YoY revenue growth, a material gross margin inflection to 55%, expanding treatment center footprint (80+ centers) and multiple near-term clinical data catalysts. Financially, operating and net losses narrowed and the company secured a strategic credit facility that, combined with revenue expectations, extends cash runway into mid-2028. Offsetting risks highlighted include continued quarterly losses, higher SG&A related to commercialization and one-time charges, sustained R&D burn, some seasonality/visibility concerns, and contingent tranches of financing tied to milestones. On balance, the positive commercial execution, margin improvement, and funded runway outweigh the remaining operational and financing risks described on the call.View all AUTL earnings summariesAUTL Stock 12 Month Forecast
Average Price Target
$7.70
▲(226.27% Upside)
Technical Analysis
Fate Therapeutics
―
Allogene Therapeutics
―
Nkarta
―
Century Therapeutics
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
<0.01% Insiders
0.36% Mutual Funds
0.17% Other Institutional Investors
98.66% Public Companies and
Individual Investors